At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FGEN FibroGen
Market Closed 01-02 16:00:00 EST
9.16
+0.38
+4.33%
盘后9.16
+0.000.00%
16:59 EST
High9.32Low8.73Vol28.23K
Open8.75D1 Closing8.78Amplitude6.78%
Mkt Cap37.06MTradable Cap33.19MTotal Shares4.05M
T/O254.16KT/O Rate0.78%Tradable Shares3.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

FDA Grants Orphan Drug Designation to FibroGen's Roxadustat for Myelodysplastic Syndromes
Reuters  ·  2025-12-15
FDA Grants Orphan Drug Designation to FibroGen's Roxadustat for Myelodysplastic Syndromes
FibroGen Inc - to File Phase 3 Protocol in Q4 2025
THOMSON REUTERS  ·  2025-12-15
FibroGen Inc - to File Phase 3 Protocol in Q4 2025
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
THOMSON REUTERS  ·  2025-12-15
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
FibroGen to Present at Oppenheimer Movers in Rare Disease Summit
Reuters  ·  2025-12-03
FibroGen to Present at Oppenheimer Movers in Rare Disease Summit
Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)
TIPRANKS  ·  2025-11-11
Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)
FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties
TIPRANKS  ·  2025-11-11
FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties
FibroGen’s Strategic Moves and Financial Highlights
TIPRANKS  ·  2025-11-11
FibroGen’s Strategic Moves and Financial Highlights
FibroGen reports Q3 EPS ($3.25), consensus ($4.01)
TIPRANKS  ·  2025-11-11
FibroGen reports Q3 EPS ($3.25), consensus ($4.01)
FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
Benzinga  ·  2025-11-11
FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate
FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million
Reuters  ·  2025-11-11
FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million
FibroGen Inc: Q3 EPS $49.61
THOMSON REUTERS  ·  2025-11-11
FibroGen Inc: Q3 EPS $49.61
FibroGen Inc expected to post a loss of $4.00 a share - Earnings Preview
Reuters  ·  2025-11-08
FibroGen Inc expected to post a loss of $4.00 a share - Earnings Preview
BRIEF-Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC Filing
Reuters  ·  2025-11-07
BRIEF-Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC Filing
FibroGen Receives $6.4 Million Payment from AstraZeneca
TIPRANKS  ·  2025-11-07
FibroGen Receives $6.4 Million Payment from AstraZeneca
FibroGen Receives $6.4 Million Payment From AstraZeneca Following China Operations Sale
Reuters  ·  2025-11-07
FibroGen Receives $6.4 Million Payment From AstraZeneca Following China Operations Sale
BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy
Reuters  ·  2025-09-25
BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy
William Blair Remains a Hold on FibroGen (FGEN)
TIPRANKS  ·  2025-09-24
William Blair Remains a Hold on FibroGen (FGEN)
FibroGen Price Target Maintained With a $43.00/Share by HC Wainwright & Co.
Dow Jones  ·  2025-09-24
FibroGen Price Target Maintained With a $43.00/Share by HC Wainwright & Co.
FibroGen’s Strategic and Financial Advancements: A Positive Outlook on FG-3246 and Roxadustat
TIPRANKS  ·  2025-09-24
FibroGen’s Strategic and Financial Advancements: A Positive Outlook on FG-3246 and Roxadustat
BRIEF-FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Reuters  ·  2025-09-24
BRIEF-FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Introduction

Company Name.
FibroGen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Issue price:
--